Almirall ALM.MC
Almirall is a Spanish pharmaceutical company specializing in medical and aesthetic dermatology, developing and marketing innovative branded products in Europe and the United States. Almirall shows solid revenue growth (13%) and exceptional earnings growth (435%), with a healthy balance sheet (ND/EBITDA of 0.04), but its valuation is demanding (P/E 37.29) and momentum is negative (-12.17% over 12 months).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Almirall is a Spanish pharmaceutical company specializing in medical and aesthetic dermatology, developing and marketing innovative branded products in Europe and the United States. Almirall shows solid revenue growth (13%) and exceptional earnings growth (435%), with a healthy balance sheet (ND/EBITDA of 0.04), but its valuation is demanding (P/E 37.29) and momentum is negative (-12.17% over 12 months).
Score by category
| Category | Score |
|---|---|
| Financial health | 7.6 |
| Quality / Moat | 5.2 |
| Valuation | 5.3 |
| Growth | 8.6 |
| Dividend | 5.9 |
| Momentum | 2.0 |
| Risk & Context | 7.8 |
OVERALL SCORE: 6.2/10
Context and risks
Elevated governance risk in Spain due to weak minority shareholder protection and legal uncertainty, justifying a moderate additional penalty on base risk.
News considered in the analysis
- Almirall SA (STU:E2Z) Q2 2026 Earnings Call Highlights: Strong Growth in Dermatology and ... — Confirma el fuerte crecimiento en dermatología, su negocio principal, pero es información ya parcialmente conocida por el mercado.
- Almirall (BME:ALM) Stock Valuation Check After Mixed Growth And High P/E Ratio — Análisis de valoración sin información nueva; el PER elevado ya está reflejado en las notas cuantitativas.
- Evotec (EVO) Nominates First Preclinical Development Candidate from Almirall Alliance — Hito en la alianza con Evotec que valida el pipeline, pero está en fase preclínica y el impacto en beneficios es lejano e incierto.
- Assessing Almirall (BME:ALM) Valuation After Recent Mixed Share Price Momentum — Artículo de valoración sin información nueva relevante.
- Assessing Almirall (BME:ALM) Valuation After Strong Full-Year Results And Optimistic 2026 Sales Guidance — Guía de ventas optimista para 2026, ya comunicada y en gran parte descontada; refuerza la nota de crecimiento.
Verdict: Hold; growth and balance sheet are attractive, but high valuation and weak momentum limit upside potential in the short term.
Main risk: The demanding valuation (P/E 37.29) leaves little room for error if earnings growth does not materialize as expected.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →